Acute coronary syndrome and lipid-lowering therapy : Does the IMPROVE-IT study make any difference?;Syndrome coronarien aigu et traitement hypolipémiant L'étude IMPROVE-IT change-t-elle la donne ?

Revue Medicale de Liege

Volumn 70, Issue 9, 2015, Pages 450-455

  Lancellotti, P ^a   Pierard L A ^b   Scheen, A J ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acute coronary syndrome; Cholesterol; Ezetimibe; Outcome; Statin

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROGNOSIS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84941556419     PISSN: 0370629X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Reiner Z, Catapano AL, De Backer G, et al. ESC/ EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011, 32, 1769-1818.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129, S1-45.
3. Descamps OS, De Backer G, Annemans L, et al. Les nouvelles recommandations Européennes pour le traitement des dyslipidémies en prévention cardiovasculaire. Rev Med Liège, 2012, 67, 118-127.
4. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J, 2012, 33, 1635-1701.
5. Scheen AJ. Le médicament du mois. Ezétimibe (Ezetrol®). Rev Med Liège, 2004, 59, 246-250.
6. Scheen AJ, Radermecker RP. Le médicament du mois. Combinaison fixe ézétimibe/simvastatine (Inegy®). Rev Med Liège, 2007, 62, 585-590.
7. Scheen AJ, Radermecker RP. Ezétimibe (Ezetrol®) chez les patients diabétiques. Rev Med Liège, 2009, 64, 606-611.
8. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med, 2008, 358, 1431-1443.
9. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med, 2008, 359, 1343-1356.
10. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet, 2011, 377, 2181-2192.
11. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015, 372, 2387-2397.
12. Cannon CP, Braunwald E, McCabe CH, et al. and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350, 1495-1504.
13. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA, 2005, 294, 2437-2445.
14. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011, 365, 2255-2267.
15. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012, 367, 2089-2099.
16. Stitziel NO, Won HH, Morrison AC, et al. Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med, 2014, 371, 2072-2082.
17. Descamps OS, De Backer G, Scheen AJ, et al. Étude IMPROVE-IT : Bénéfice de l'ajout d'ézétimibe à une statine pour prévenir les maladies cardiovasculaires, commentaire de la Société Belge d'Athérosclérose / Belgian Lipid Club. Louvain Med, 2014, 133, 692-701.
18. Jarcho JA, Keaney JF Jr. Proof that lower is better. LDL cholesterol and IMPROVE-IT. N Engl J Med, 2015, 372, 2448-2450.
19. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
20. Radermecker RP, Scheen AJ. Comment optimaliser le traitement hypolipidémiant: Ne pas oublier la problématique du défaut d'observance. Rev Med Liège, 2010, 65, 311-317.
21. Scheen AJ, Kulbertus H. Prevention cardio-vasculaire par les statines: Faut-il encore doser le cholesterol? Rev Med Liège, 2003, 58, 191-197.
22. Scheen AJ, Descamps OS. Approche personnalisée du traitement des dyslipidémies. Rev Med Liège, 2015, 70, 292-298.
23. Roffi M, Patrono C, Collet JP, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J, 2015, in press.
24. Husain NE, Hassan AT, Elmadhoun WM, Ahmed MH. Evaluating the safety of Liptruzet (ezetimibe and atorvastatin) : What are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? Expert Opin Drug Saf, 2015, Jul 2:1-11. [Epub ahead of print]